Ronald Gust

TL;DR: This review describes the advances that have been achieved in using transition metal complexes containing NHC ligands as antitumor agents and clearly demonstrate the great potential of metal-NHC complexes as antitUMor agents.

TL;DR: Preclinical and clinical investigations showed that the development of new metal agents with modes of action different from cisplatin is possible, and complexes with iron, cobalt, or gold central atoms have shown promising results in preclinical studies and compounds with titanium, ruthenium, or galliumcentral atoms have already been evaluated in phase I and phase II trials.

TL;DR: Cell viability studies of HT29 colon cancer cells treated with the CO-releasing compound [Mn(CO)(3)(tpm)]PF(6) revealed a significant photoinduced cytotoxicity comparable to that of established agent 5-fluorouracil (5-FU).

TL;DR: A series of five ruthenium(II) polypyridyl complexes [Ru(bpy)2(NN)]Cl2 was tested against human HT‐29 and MCF‐7 cancer cell lines and indicates that its biological activity is related to modifications in cell morphology or cell–cell and cell–matrix contacts.

TL;DR: The presented results indicate that cobalt-alkyne complexes of the Co-ASS type, represent a new class of organometallic cytostatics with a mode of drug action in which COX inhibition probably plays a major role.